Ligand Pharmaceuticals Incorporated
NASDAQ:LGND · NASDAQ Global Market
+$2.89 today
Vol 0.55M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.2%
avg 19.5%
ROIC
2.4%
avg 7.0%
ROA
8.0%
avg 10.7%
Analysis
ROE is currently the strongest return metric at 12.2% versus its period average of 19.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Todd C. Davis | Chief Executive Officer & Director | $1.51M | — | 65 | $199,381.00 | 0.99% |
Octavio Espinoza | Chief Financial Officer | $895,518.00 | — | 55 | $17,407.00 | 0.09% |
Andrew T. Reardon | Chief Legal Officer & Secretary | $758,766.00 | — | 51 | $45,891.00 | 0.23% |
Melanie J. Herman | Executive Director of Investor Relations and Financial Planning & Analysis | $275,099.00 | — | 47 | — | — |
Paul J. Hadden | Senior Vice President of Investments & Business Development | — | — | — | — | — |
Karen R. Reeves | Senior Vice President of Investments & Head of Clinical Strategy | — | — | 76 | $1,161.00 | <0.01% |
Keith Marschke | Senior Vice President of Biology & Scientific Affairs | — | — | — | — | — |
Vincent D. Antle | Senior Vice President of Technical Operations & QA - Capitsol | — | — | 57 | — | — |
Patrick Lucy | Senior Vice President & CBO Protein Expression Business | — | — | — | — | — |
Richard Baxter | Senior VP of Investment Operations | — | — | 63 | — | — |
Scott Plesha | Chief Executive Officer of Pelthos Therapeutics | — | — | 61 | — | — |
Lauren Hay | Vice President of Strategic Planning & Investment Analytics | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
103
$17.55M
Net Sentiment
$17.55M
Net selling
Most Active
KOZARICH JOHN W
43 transactions
1–10 of 103
Analysis
Insiders reported 0 buys worth $0.00 and 103 sells worth $17.55M over the last 12 months. That adds up to net selling of $17.55M. KOZARICH JOHN W was the most active insider with 43 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +2.2% (15yr)2 analysts |
| Revenue | N/A | N/A | +31.8% | +13.9% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | +1.8% (15yr)2 analysts |
| EBIT | N/A | N/A | +262.4% | +13.0% (15yr)2 analysts |
Analysis
Recent growth has been strongest in EBIT at +262.4% over three years. Forward estimates point to Revenue at +13.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Belite Bio, Inc
NASDAQ:BLTE
$5.96B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.95B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.32B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.76B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.68B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.62B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.56B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.27B
Soleno Therapeutics, Inc.
SLNO
$2.76B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.96B
Who manages LGND?
Ligand Pharmaceuticals Incorporated (LGND) lists 12 active executives. The top listed executive is Paul J. Hadden, Senior Vice President of Investments & Business Development.
Are LGND insiders buying or selling?
Recent insider activity shows net selling of $3.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.